Quarterly Activities and Cash Flow Report – Q4 2024

Report Highlights:

• Amplia Therapeutics Ltd. (ASX: ATX) has made significant progress in its Phase 2a ACCENT trials for pancreatic cancer treatment, recruiting 12 patients for the second and final cohort, bringing the total to 50 patients. The company also recorded three additional confirmed partial responses in the initial 26-patient cohort, increasing the total to 9 confirmed partial responses and achieving an objective response rate of 35%, which is notably higher than the historical benchmark of 23%​.
• The company strengthened its research and development efforts by initiating a preclinical collaboration with Korean biotechnology company Next&Bio to evaluate the effectiveness of Amplia’s FAK inhibitors in combination with kRas inhibitors for pancreatic cancer treatment. This partnership aims to explore the potential of these inhibitors in treating pancreatic, lung, and colorectal cancers, reinforcing Amplia’s commitment to expanding its therapeutic pipeline​.
• Amplia concluded the quarter with a strong cash position of USD 8.6MM / AUD 13.7 MM, significantly bolstered by the recent capital raise USD 8.1MM / AUD 13MM to support the completion of the Phase 2a ACCENT trial and the newly approved U.S.-based trials. The company recorded a net operating cash outflow of USD 1.9MM / AUD 3MM, primarily allocated to R&D and corporate expenses, while also settling payments to related entities.